intraportal islet autotransplantation

Biologic

intraportal islet autotransplantation is one of 38 biologic programs targeting Adenocarcinoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaActive, not recruiting

AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

337 competitors in Adenocarcinoma

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

47 2

Gemzar

Johnson & Johnson

Phase 3

16 3

Taxotere

AAvyxa

Phase 3

19 4

Iressa

AstraZeneca

Phase 3

4 5

Cyramza

Eli Lilly

Phase 3

4 6

Opdivo

Bristol-Myers Squibb

Phase 3

3 7

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

11 8

DATROWAY

Daiichi Sankyo

Phase 3

1 9

Erbitux

IImclone

Phase 3

5 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 1/2Recruiting

Adenocarcinoma

NCT05116072

Clinical

Trials by Indication[1]

Adenocarcinoma1 trial

Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula

Recruiting·UUniversity Hospital, Lille·Phase 1/2·NCT05116072·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for intraportal islet autotransplantation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intraportal islet autotransplantation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intraportal islet autotransplantation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Lille company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: UUniversity Hospital, Lille

intraportal islet autotransplantation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News